Page 1,428«..1020..1,4271,4281,4291,430..1,4401,450..»

Stem Cell Albuquerque New Mexico 87181

Posted: August 10, 2018 at 2:43 am

Stem cell treatment has become a popular argument in the international medical scene. This highly questionable therapy has actually received combined opinions from various stakeholders in the health care market and has likewise attracted the attention of politicians, religious leaders and the general population at large. Stem cell treatment is thought about an innovative treatment for people struggling with a vast array of degenerative conditions. Some common questions regarding this treatment are addressed below.

Are you a stem cell therapy doctor in Albuquerque NM 87181? Contact us for more information about joining our website.

Stem cells can be described as blank state or non-specialized cells that have the capability to become specialized cells in the body such as bone, muscle, nerve or organ cells. This means that these special cells can be used to regrow or develop a large range of damaged cells and tissues in the body. Stem cell treatment is therefore a treatment that targets at accomplishing tissue regeneration and can be used to cure health conditions and health problems such as osteoarthritis, degenerative disc disease, spinal cord injury, muscular degeneration, motor nerve cell illness, ALS, Parkinsons, heart problem and much more.

Being a treatment that is still under research, stem cell therapy has actually not been completely accepted as a feasible treatment choice for the above discussed health conditions and illnesses. A great deal of research study is currently being performed by researchers and medical professionals in numerous parts of the world to make this treatment feasible and effective. There are nevertheless different constraints enforced by federal governments on research involving embryonic stem cells.

Presently, there havent been lots of case studies performed for this kind of treatment. Nevertheless, with the few case studies that have been conducted, among the significant issues that has been raised is the boost in a clients threat of developing cancer. Cancer is triggered by the rapid reproduction of cells that tend not to pass away so easily. Stem cells have been related to comparable development elements that might cause formation of growths and other cancerous cells in clients.

Contact us for more information about stem cell provider near Albuquerque NM 87181

Stem cells can be drawn out from a young embryo after conception. These stem cells are typically described as embryonic stem cells. After the stem cells are drawn out from the embryo, the embryo is ended. This is generally one of the significant reasons for debate in the field of stem cell studio. Lots of people argue that termination of an embryo is unethical and inappropriate.

Stem cells can still be obtained through other methods as they can be found in the blood, bone marrow and umbilical cables of adult human beings. Regular body cells can likewise be reverse-engineered to become stem cells that have actually limited abilities.

New research has nevertheless shown promise as researchers aim at establishing stem cells that do not form into growths in later treatment stages. These stem cells can therefore successfully transform into other kinds of specialized cells. This treatment is for that reason worth investigating into as lots of clients can gain from this advanced treatment.

Find a stem cell therapy in Albuquerque NM 87181

59

Main address:Albuquerque, New Mexico, 87181

Go here to see the original:
Stem Cell Albuquerque New Mexico 87181

Posted in New Mexico Stem Cells | Comments Off on Stem Cell Albuquerque New Mexico 87181

Homepage | Diabetes Research Connection

Posted: August 9, 2018 at 5:45 am

WE NEED TO INVEST IN YOUNG SCIENTISTS

"There is a need for increased collaborative efforts to eradicate diabetes. We need to invest in young scientists with new and fresh ideas that are willing to dedicate their career to study diabetes. Federal funding for young investigators in basic research is getting harder to acquire, so private funding is critical to invest in novel ideas to help young scientists in their quest for the cure."

Agata Jurczyk, Ph.D.

University of Massachusetts Medical School

A TREMENDOUS NEW WAY TO FUND YOUNG RESEARCH INVESTIGATORS

"DRC is a tremendous new way to fund brilliant young research investigators The Diabetes Research Connection is a tremendous new way to fund brilliant young research investigators in the early stages of their careers -- when they need our support the most. These fresh, innovative minds will spearhead scientific discoveries, and will ensure that we have a robust diabetes drug/device pipeline for years to come. I applaud the founders of DRC for..."

Lorraine Stiehl

Diabetes Research Advocate, Board Member JDRF, Board Member Diabetes Hands Foundation

I BELIEVE THE MISSION OF DIABETES RESEARCH CONNECTION IS VITAL!

"Entering my fourth decade of type 1 diabetes research, it is quite remarkable to look back and see how research seeking to identify answers to the questions of how this disease develops and how the disorder could be cured have changed. No one could have envisioned the difficulty of obtaining research funding, especially for young people. For these reasons, I believe the mis..."

Mark Atkinson, Ph.D.

Director, University of Florida Diabetes Institute

ADVANCING EFFORTS OF EARLY-CAREER SCIENTISTS

The Diabetes Research Connection will advance the efforts of early-career scientists whose innovative proposals for diabetes investigations might be overlooked by government funding agencies in favor of more conventional research.

Alberto Hayek, M.D.

Professor Emeritus, UC San Diego

INCREDIBLY GRATEFUL FOR THE FUNDING WE RECEIVED

"Thanks to the Diabetes Research Connection, I was able to undertake my investigation, Can we engineer a patients immune cells to stop the autoimmune attack that causes type 1 diabetes? The Brusko lab is incredibly grateful for the $50,000 we received to drive this exciting research project forward."

Todd Brusko, Ph.D.

University of Florida

SOMETIMES DIABETES SIMPLY CANNOT BE CONTROLLED

I support the Diabetes Research Connection because I believe that a cure is possible and may very well lie in a different direction than where traditional research has been focused. I want to support new promising paradigms of thought that are scientifically endorsed by experts in the field of diabetes. I think the Diabetes Research Connection is the perfect platform for this type of investigat..."

Amy Adams

Donor, Chair of Lay Review Committee, Diabetes Research Connection

DRC IS COMMITTED TO THE CURE

"Committed To The Cure The Diabetes Research Connection will become a powerful breeding ground for new ideas in T1D research in the context of a supportive and enthusiastic community of donors.

C.C. King

Associate Research Scientist, Pediatric Diabetes Research Center, Department of Pediatrics, UCSD

A GROUNDBREAKING EFFORT TO REVOLUTIONIZE HOW WE FUND DIABETES RESEARCH

"I am passionate about User Experience and developing technologies that create meaningful communities that are focused on making a difference. So I am thrilled at this groundbreaking effort to revolutionize how we fund diabetes research. Most important to me is the effort to bridge the gap between scientist and supporters to cultivate a community of connection. The Diabetes Research Connection aspires to create a co..."

Jarryd Wafer

Senior Designer at FindTheBest.com

Continued here:
Homepage | Diabetes Research Connection

Posted in Diabetes | Comments Off on Homepage | Diabetes Research Connection

Hanson Diabetes Center | Your best source for Diabetes …

Posted: August 9, 2018 at 5:45 am

We are your best source for diabetes management and education in Charlotte, Sarasota and DeSoto counties. We are committed to providing you with the most current information and treatments for managing your diabetes. Our Living Smart Diabetes Self-Management Program is recognized by the American Diabetes Association with classes offered monthly in our state-of-the-art conference room located next to our Diabetes Center.

Hanson Diabetes Center also provides state-of-the-art thyroid evaluation and management. Lenita Hanson M.D., F.A.C.E., CDE, CPI, our board certified endocrinologist, is skilled in thyroid sonography and fine needle aspiration of thyroid nodules. Her thyroid expertise ranges from diagnosing basic thyroid imbalance to the management of thyroid cancer. Dr. Hanson also provides other endocrine services on a limited basis.

Our sister company, Hanson Clinical Research Center, is located next to the Diabetes Center. It provides an opportunity for anyone interested in becoming a part of clinical research to participate in our current diabetes related trials.

Read the original post:
Hanson Diabetes Center | Your best source for Diabetes ...

Posted in Diabetes | Comments Off on Hanson Diabetes Center | Your best source for Diabetes …

Stem Cell Transplant – New York – Park Avenue Stem Cell …

Posted: August 9, 2018 at 5:44 am

Stem Cell Therapy is part of an exciting new field in medicine called Regenerative Medicine. In traditional medical treatment, we rely on NSAIDs, Steroids, other pharmaceuticals or surgery. At Park Avenue Stem Cell as part of the Cell Surgical Network(CSN), we are investigating the use of stromal vascular fraction(SVF) containing Adipose Derived Stem Cells in the mitigation of cellular degenerative conditions such as chronic inflammation, arthritis, COPD, Alzheimers Disease and many other conditions. This research is part of an FDA approved preliminary safety study a IRB numbers ICSS-2016-001 though ICSS-2016-21, and we have maintained an extensive database that now includes more than 5000 patients. Please refer to A Prospective Safety Study of Autologous Adipose Derived Stromal Vascular Fraction Using a Specialized Surgical Processing System by Mark Berman, M.D. and Elliot Lander, M.D., Am. J Cosmetic Surgery, 2017 for additional information.

Stem Cell Treatments Starting at $3995Schedule Your Appointment Now >>

Read the original here:
Stem Cell Transplant - New York - Park Avenue Stem Cell ...

Posted in New York Stem Cells | Comments Off on Stem Cell Transplant – New York – Park Avenue Stem Cell …

Stem Cell – Joint Preservation Institute of Iowa

Posted: August 9, 2018 at 5:41 am

Orthobiologic is the broad term for using biologic products in orthopaedic surgeryranging from stem cell injections to matched donor bone and cartilage transplantation. This is an exciting and promising new field in orthopaedic surgery and Dr. Richard Goding offers all of the newest, highest technology treatments, as well as the time-tested gold standards.

Each patient and each joint has its own story, and what may be the best treatment for one patient may not be the most appropriate for another patient.Dr. Richard Goding is one of the few orthopaedic surgeons in the nation who offers the full spectrum of treatments in this field. He offers each patient a personalized plan that goes beyond the initial treatment Dr. Richard Goding remains involved in your care until your joint problem is solved.

The Joint Preservation Institute of Iowa is now offering stem cell therapy in Des Moines.

Dr. Richard Goding is one of the firstorthopaedic surgeons in the nation to offer this treatment. He uses autologous stem cell therapy and the regenerative power of mesenchymal stem cells to give patients another treatment option for dealing with orthopaedic conditions, such as osteoarthritis and other degenerative joint conditions.Read More >

MACI is a new procedure that treats the articular cartilage defects of the knee by assisting regeneration of cartilage and restoring flexibility. Articular cartilage is a tissue that covers the surface of the joints and is responsible for pain-free movement of the bones within the joint. If the articular cartilage is damaged, the ends of the bones rub against each other, causing pain. MACI is indicated for patients with significant cartilage defects causing joint pain, swelling and catching in the knee.Read More >

Osteoarticular transfer system (OATS) is a surgical procedure used to treat isolated cartilage defects, which are usually 10 to 20 milimeters in size. The procedure transfers cartilage plugs taken from non-weight bearing areas of the joint and to the damaged areas of the joint.Read More >

DeNovo grafts are tissue grafts used in cartilage repair. These grafts consist of cartilage tissue collected from donors or grown in the laboratory using human donated cartilage cells. There are two forms DeNovo ET (engineered tissue) and DeNovo NT (natural tissue).Read More >

Chondrofix Osteochondral Allograft takes the repair of full-thickness osteochondral lesions to a new level of convenience. Chondrofix is the first off-the-shelf osteochondral allograft, and each graft combines the inherent qualities of donated human bone and cartilage with the advantages of simplicity and safety. It is intended for homologous use to repair osteochondral lesions in diarthrodial joints. Read More >

Subchondroplasty is a minimally invasive, fluoroscopically assisted procedure that targets and fills subchondral bone defects through the delivery of AccuFill BSM, a highly porous, nanocrystalline injectable calcium phosphate.Read More >

Superior capsular reconstruction is a new procedure for treating large unfixable rotator cuff tears. This procedure, which is done on an outpatient basis almost fully arthroscopically, uses a graft to reconstruct the shoulder capsule when the rotator cuff tendon tears are too large to repair. By reconstructing the capsule, a cushion is placed between the ball of the shoulder joint and the acromion bone. Additionally, the joint is held in anatomic position, allowing for restoration of normal shoulder function.Read More >

Total shoulder replacement is a very successful procedure performed for shoulder arthritis. However, there are some significant limitations. The shoulder replacement does not tolerate heavy use and will wear out over time, making it a poor choice for younger patients. Read More >

Read more:
Stem Cell - Joint Preservation Institute of Iowa

Posted in Iowa Stem Cells | Comments Off on Stem Cell – Joint Preservation Institute of Iowa

Molecular Genetics | ARUP Laboratories

Posted: August 7, 2018 at 7:43 pm

2007228 5-Fluorouracil (5-FU) Toxicity and Chemotherapeutic Response, 5 Mutations 5-Fluorouracil Sensitivity 5-FU, 5-Fluorouracil Toxicity and Chemotherapeutic Response Panel, Pharmacogenetics (PGx), Colorectal Cancer 2012166 Dihydropyrimidine Dehydrogenase (DPYD) Genotyping, 3 Mutations 5-Fluorouracil Sensitivity DYPD 5-Fluorouracil toxicity5-FU toxicity5-FU toxicity5FU toxicityAdrucil (DPYD) Genotyping, 3 MutationsXeloda (capecitabine) (DPYD) Genotyping, 3 Mutations DPDUftoral (tegafur/uracil) (DPYD) Genotyping, 3 Mutations 0051266 Achondroplasia (FGFR3) 2 Mutations Achondroplasia AD PCR, Skeletal Dysplasias, Neuroblastoma 0051265 Achondroplasia Mutation, Fetal Achondroplasia AD PCR FE, Skeletal Dysplasias 2011708 Alpha Globin (HBA1 and HBA2) Sequencing and Deletion/Duplication Alpha Thalassemia AG FGA, 2011622 Alpha Globin (HBA1 and HBA2) Deletion/Duplication Alpha Thalassemia HBA DD, Alpha thalassemia, alpha globin mutations, alpha globin gene analysis, A globin 0051495 Alpha Thalassemia (HBA1 & HBA2) 7 Deletions Alpha Thalassemia ALPHA THAL, Hemoglobinopathies 2002398 Alport Syndrome, X-linked (COL4A5) Sequencing and Deletion/Duplication Alport Syndrome ALPORT FGARenal disease, chronic kidney disease, hematuria 0051786 Alport Syndrome, X-linked (COL4A5) Sequencing Alport Syndrome ALPORT FGSRenal disease, chronic kidney disease, hematuria 2013341 Apolipoprotein E (APOE) Genotyping, Alzheimer Disease Risk Alzheimer's Disease APOE AZ 2005077 Angelman Syndrome and Prader-Willi Syndrome by Methylation Angelman Syndrome AS PWS, Angelman, Prader-Willi, Neurocognitive Impairments 2005564 Angelman Syndrome (UBE3A) Sequencing Angelman Syndrome UBE3A FGS 2012232 Angelman Syndrome and Prader-Willi Syndrome by Methylation, Fetal Angelman Syndrome AS PWS FE Prader-Labhart-Willi Syndrome, AS, PWS 2006540 Aortopathy Panel, Sequencing and Deletion/Duplication, 21 Genes Aortopathies AORT PANEL, Thoracic aortic aneurysms, dissections, familial thoracic TAAD AAT, ACTA2 (AAT6), FBN1, MYH11 (AAT4), MYLK (AAT7), SMAD3, TGFBR1 (AAT5), TGFBR2 (AAT3), SLC2A10, FBN2, COL3A1ACTA2, CBS, COL3A1, COL5A1, COL5A2, FBN1, FBN2, MYH11, MYLK, PLOD1, SKI, SLC2A10, SMAD3, SMAD4, TGFB2, TGFBR1, TGFBR2 2005584 Marfan Syndrome (FBN1) Sequencing and Deletion/Duplication Aortopathies FBN1 FGA 2005589 Marfan Syndrome (FBN1) Sequencing Aortopathies FBN1 FGS 2002705 TGFBR1 & TGFBR2 Sequencing Aortopathies LDS FGS, Loeys-Dietz, aortic aneurysm see Loeys-Dietz Syndrome Aortopathies see Marfan Syndrome and FBN1-Related Disorders Aortopathies 0055654 Apolipoprotein B Mutation Detection (G9775A, C9774T) Apolipoprotein B (APOB) APO B, Risk Markers - CVD (Non-traditional) 2013341 Apolipoprotein E (APOE) Genotyping, Alzheimer Disease Risk Apolipoprotein E (APOE) APOE AZ 2013337 Apolipoprotein E (APOE) Genotyping, Cardiovascular Risk Apolipoprotein E (APOE) APOE CR 0051415 Ashkenazi Jewish Diseases, 16 Genes Ashkenazi Jewish Panel (16 disorders) AJP, Jewish Genetic, Fanconi's, Fanconis,ABCC8, TMEM216, NEB, G6PC, DLD, BCKDHB, CLRN1, PCDH15 2013725 ABCC8-Related Hyperinsulinism, 3 Variants Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 2013745 NEB-Related Nemaline Myopathy, 1 Variant Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 0051433 Bloom Syndrome (BLM),1 Variant Ashkenazi Jewish Panel (16 disorders) BLM, Jewish Genetic 0051453 Canavan Disease (ASPA), 4 Variants Ashkenazi Jewish Panel (16 disorders) ASPA, Jewish Genetic 0051463 Dysautonomia, Familial (IKBKAP), 2 Variants Ashkenazi Jewish Panel (16 disorders) IKBKAP, Jewish Genetic Disease 0051468 Fanconi Anemia Group C, (FANCC), 2 Variants Ashkenazi Jewish Panel (16 disorders) FANCC, Jewish, Ashkenazi, Fanconi's, Fanconis, carrier testing, DNA 0051438 Gaucher Disease (GBA), 8 Variants Ashkenazi Jewish Panel (16 disorders) GBA, Jewish Genetic, Glucocerebrosidase, Glucosylceramidase 2013740 Glycogen Storage Disease, Type 1A (G6PC), 9 Variants Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 2013909 Joubert Syndrome Type 2 (TMEM216), 1 Variant Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 2013735 Lipoamide Dehydrogenase Deficiency (DLD), 2 Variants Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 2013730 Maple Syrup Urine Disease, Type 1B (BCKDHB), 3 Variants Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 0051448 Mucolipidosis Type IV (MCOLN1), 2 Variants Ashkenazi Jewish Panel (16 disorders) MCOLN1, Jewish Genetic, lysosomal 0051458 Niemann-Pick, Type A (SMPD1), 4 Variants Ashkenazi Jewish Panel (16 disorders) SMPD1, Jewish Genetic, acid sphingomyelinase, ASM, NP-A, lysosomal storage, L302P, 1bp del fsP330, R496L, R608del 0051428 Tay-Sachs Disease (HEXA), 7 Variants Ashkenazi Jewish Panel (16 disorders) HEXA, Jewish Genetic, Hex A, GM2 gangliosidosis, hexosaminidase, lysosomal storage, delta 7.6kb, IVS9(+1)G>A, 1278insTATC, IVS12(+1)G>C, G269S, R247W, R249W 2013750 Usher Syndrome, Types 1F and 3 (PCDH15 and CLRN1), 2 Variants Additional Technical Information Ashkenazi Jewish Panel (16 disorders) 2014314 Autism and Intellectual Disability Comprehensive Panel Autism Creatine, epilepsy, amino acids, organic acids, mucopolysaccharidoses (MPS), MPS, acylcarnitine, mental retardation, Fragile X, microarray 0051614 Rett Syndrome (MECP2), Full Gene Analysis Autism RETT FGA, MECP2-related, Rett, atypical Rett, neonatal encephalopathy, PPM-X, neurocognitive impairments 2002470 PTEN-Related Disorders Sequencing and Deletion/Duplication Autism PTEN FGA, PTEN hamartoma tumor, PHTS, Cowden, CS, Bannayan-Riley-Ruvalcaba, BRRS, Proteus, PS, Proteus-like, PSL, macrocephaly, autism 2004935 CDKL5-Related Disorders (CDKL5) Sequencing and Deletion/Duplication Autism CDKL5 FGA, X-linked infantile spasm 2005077 Angelman Syndrome and Prader-Willi Syndrome by Methylation Autism AS PWS, Angelman, Prader-Willi, Neurocognitive Impairments 2005564 Angelman Syndrome (UBE3A) Sequencing Autism UBE3A FGS 2010117 Beta Globin (HBB) Sequencing and Deletion/Duplication Beta Globin BG FGA, Beta thalassemia, beta globin, HBB 0050388 Beta Globin (HBB) Sequencing, Fetal Beta Globin BG SEQ FE 0051422 Beta Globin (HBB) HbS, HbC, and HbE Mutations, Fetal Beta Globin HB SCE FE 0051700 Biotinidase Deficiency (BTD), 5 Mutations Biotinidase Deficiency BTD MUT, Multiple carboxylase 0051730 Biotinidase Deficiency (BTD) Sequencing Additional Technical Information Biotinidase Deficiency BTD FGS, Multiple carboxylase 0051368 Rh Genotyping D Antigen (RhD positive/negative and RhD copy number) Blood Genotyping RHD, Hemolytic Disease of the Newborn, fetal erythroblastosis, isoimmunization, alloimmune hemolytic 0050421 RhCc Antigen (RHCE) Genotyping Blood Genotyping RH C, Hemolytic Disease of the Newborn, fetal rhesus type, alloimmunization, alloantibodies, maternal-fetal Rh incompatibility 0050423 RhEe Antigen (RHCE) Genotyping Blood Genotyping RH E, Hemolytic Disease of the Newborn, fetal rhesus type, alloimmunization, alloantibodies, maternal-fetal Rh incompatibility 0051644 Kell K/k Antigen (KEL) Genotyping Blood Genotyping KEL, Hemolytic Disease of the Newborn, K/k, Kell/Cellano 0051433 Bloom Syndrome (BLM),1 Variant Bloom Syndrome BLM, Jewish Genetic 2012026 Breast and Ovarian Hereditary Cancer Panel, Sequencing and Deletion/Duplication, 20 Genes Breast Cancer BOCAPAN, Breast Cancer, Tumor Markers, FISH, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53 2011949 Breast and Ovarian Hereditary Cancer Syndrome (BRCA1 and BRCA2) Sequencing and Deletion/Duplication Breast Cancer BRCA FGA, BRACA, HBOC 2011954 Breast and Ovarian Hereditary Cancer Syndrome (BRCA1 and BRCA2) Sequencing Breast Cancer BRCA FGS, BRACA, HBOC 2002722 PTEN-Related Disorders Sequencing Breast Cancer PTEN FGS, PTEN hamartoma tumor, PHTS, Cowden, CS, Bannayan-Riley-Ruvalcaba, BRRS, Proteus, PS, Proteus-like, PSL, macrocephaly, autism 2002470 PTEN-Related Disorders Sequencing and Deletion/Duplication Breast Cancer PTEN FGA, PTEN hamartoma tumor, PHTS, Cowden, CS, Bannayan-Riley-Ruvalcaba, BRRS, Proteus, PS, Proteus-like, PSL, macrocephaly, autism 2009313 Li-Fraumeni (TP53) Sequencing and Deletion/Duplication Breast Cancer TP53 FGA, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2009302 Li-Fraumeni (TP53) Sequencing Breast Cancer TP53 FGS, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2008398 Peutz-Jeghers Syndrome (STK11) Sequencing and Deletion/Duplication Breast Cancer STK11, STK11 FGA, hamartomatous polyps, mucocutaneous hypergigmentation 2008394 Peutz-Jeghers Syndrome (STK11) Sequencing Breast Cancer STK11, STK11 FGS, hamartomatous polyps, mucocutaneous hypergigmentation 0051453 Canavan Disease (ASPA), 4 Variants Canavan Disease ASPA, Jewish Genetic 2012032 Cancer Panel, Hereditary, Sequencing and Deletion/Duplication, 47 Genes Cancer, Hereditary CANCERPAN, Lynch syndrome, breast cancer, multiple endocrine neoplasia, melanoma, retinoblastoma, paraganglioma, Li-Fraumeni, familial adenomatous polyposis, Peutz-Jegher, HNPCC, inherited cancer, renal cancer, GI cancer, colorectal cancer, NGS cancer panel 2010183 Cardiomyopathy and Arrhythmia Panel, Sequencing (85 Genes) and Deletion/Duplication (83 Genes) Cardiomyopathy CARDIACPAN, Hypertrophic cardiomyopathy (HCM), Dilated cardiomyopathy (DCM), Arrhythmogenic right vernticular cardiomyopathy (ARVC), Left ventricular noncompaction (LVNC), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS), Long QT syndrome (LQTS), Romano-Ward, Short QT syndrome (SQTS), ABCC9, ACTC1, ACTN2, AKAP9, ANK2, ANKRD1, CACNA1C, CACNB2, CASQ2, CAV3, CORIN, COX15, CSRP3, CTF1, DES, DMD, DSC2, DSG2, DSP, DTNA, EMD, EYA4, FKRP, FKTN, FXN, GAA, GLA, GPD1L, ILK, JPH2, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNQ1, KLHL3, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYH10, MYL2, MYL3, MYLK2, MYOT, MYOZ2, MYPN, NEXN, OBSCN, PKP2, PLN, PRKAG2, RBM20, RYR2, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SCO2, SGCA, SGCB, SGCD, SGCG, SLC25A4, SNTA1, SYNE1, TAZ, TCAP, TGFB3, TMEM43, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TRPM4, TTN, TTR, VCLABCC9, ACTC1, ACTN2, AKAP9, ANK2, ANKRD1, CACNA1C, CACNB2, CASQ2, CAV3, CORIN, COX15, CSRP3, CTF1, DES, DMD, DSC2, DSG2, DSP, DTNA, EMD, EYA4, FKRP, FKTN, FXN, GAA, GLA, GPD1L, ILK, JPH2, JUP, KCNE1, KCNE2, KCNE3, KCNH2, KCNJ2, KCNQ1, KLHL3, LAMA4, LAMP2, LDB3, LMNA, MYBPC3, MYH6, MYH7, MYH10, MYL2, MYL3, MYLK2, MYOT, MYOZ2, MYPN, NEXN, OBSCN, PKP2, PLN, PRKAG2, RBM20, RYR2, SCN1B, SCN2B, SCN3B, SCN4B, SCN5A, SCO2, SGCA, SGCB, SGCD, SGCG, SLC25A4, SNTA1, SYNE1, TAZ, TCAP, TGFB3, TMEM43, TMPO, TNNC1, TNNI3, TNNT2, TPM1, TRPM4, TTN, TTR, VCL, arrhythmogenic right ventricular cardiomyopathy (ARVC), Brugada syndrome (BrS), catecholaminergic polymorphic ventricular tachycardia (CPVT), dilated cardiomyopathy (DCM), hypertrophic cardiomyopathy (HCM), left ventricular noncompaction (LVNC), long QT syndrome (LQTS), Romano-Ward, short QT syndrome (SQTS) 2004203 Carnitine Deficiency, Primary (SLC22A5) Sequencing and Deletion/Duplication Carnitine Deficiency PCD FGA, OCTN2, carnitine uptake 0051682 Carnitine Deficiency, Primary (SLC22A5) Sequencing Carnitine Deficiency PCD FGS, OCTN2, carnitine uptake 0051415 Ashkenazi Jewish Diseases, 16 Genes Carrier Screening Panels AJP, Jewish Genetic, Fanconi's, Fanconis,ABCC8, TMEM216, NEB, G6PC, DLD, BCKDHB, CLRN1, PCDH15 3000258 Genetic Carrier Screen, (CF, FXS, and SMA) with Reflex to Methylation Carrier Screening Panels CF FX SMA 2014674 Expanded Carrier Screen Genotyping Carrier Screening Panels ECS GENO 2014671 Expanded Carrier Screen Genotyping with Fragile X Carrier Screening Panels ECS GEN FX 2014680 Expanded Carrier Screen by Next Generation Sequencing Carrier Screening Panels ECS SEQ 2014677 Expanded Carrier Screen by Next Generation Sequencing with Fragile X Carrier Screening Panels ECS SEQ FX 2004931 CDKL5-Related Disorders (CDKL5) Sequencing Additional Technical Information CDKL5-Related Disorders CDKL5 FGS, X-linked infantile spasm 2004935 CDKL5-Related Disorders (CDKL5) Sequencing and Deletion/Duplication CDKL5-Related Disorders CDKL5 FGA, X-linked infantile spasm 2005018 Celiac Disease (HLA-DQA1*05, HLA-DQB1*02, and HLA-DQB1*03:02) Genotyping Do not use in the initial evaluation for celiac disease. Useful in ruling out celiac disease (CD) (high negative predictive value) in selective clinical situations such as: Equivocal small-bowel histologic finding (Marsh I-II) in seronegative individuals Evaluation of individuals on a gluten-free diet (GFD) in whom no testing for CD was done before GFD Celiac Disease HLA CELIAC 2002965 Von Hippel-Lindau (VHL) Sequencing and Deletion/Duplication Central Nervous System Cancer VHL FGA, Brain Tumors, Pheochromocytoma 2002970 Von Hippel-Lindau (VHL) Sequencing Central Nervous System Cancer VHL FGS, Congenital polycythemia 2012032 Cancer Panel, Hereditary, Sequencing and Deletion/Duplication, 47 Genes Central Nervous System Cancer CANCERPAN, Lynch syndrome, breast cancer, multiple endocrine neoplasia, melanoma, retinoblastoma, paraganglioma, Li-Fraumeni, familial adenomatous polyposis, Peutz-Jegher, HNPCC, inherited cancer, renal cancer, GI cancer, colorectal cancer, NGS cancer panel 2009313 Li-Fraumeni (TP53) Sequencing and Deletion/Duplication Central Nervous System Cancer TP53 FGA, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2009302 Li-Fraumeni (TP53) Sequencing Central Nervous System Cancer TP53 FGS, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2012160 Charcot-Marie-Tooth Type 1A (CMT1A)/Hereditary Neuropathy with Liability to Pressure Palsies (HNPP), PMP22 Deletion/Duplication Charcot-Marie-Tooth Disease CMT DD, AARS, AIFM1, ARHGEF10, ATL1, ATP7A, BAG3, BICD2, BSCL2, CCT5, DCTN1, DHTKD1, DNAJB2, DNM2,DNMT1, DYNC1H1, EGR2, FAM134B, FBLN5, FGD4, FIG4, GAN, GARS, GDAP1, GJB1, GNB4, HARS, HEXA, HINT1, HK1, HOXD10,HSPB1, HSPB3, HSPB8, IGHMBP2, IKBKAP, INF2, KARS, KIF1A, KIF1B, KIF5A, LAS1L, LITAF, LMNA, LRSAM1, MARS, MED25, MFN2,MPZ, MTMR2, MYH14, NDRG1, NEFL, NGF, NTRK1, PDK3, PLEKHG5, PMP22, PRNP, PRPS1, PRX, RAB7A, REEP1, SBF1, SBF2, SCN9A,SETX, SH3TC2, SLC12A6, SLC5A7, SOX10, SPTLC1, SPTLC2, TDP1, TFG, TRIM2, TRPV4, WNK1, YARS 2012155 Charcot-Marie-Tooth (CMT) and Related Hereditary Neuropathies, PMP22 Deletion/Duplication with Reflex to Sequencing Panel Charcot-Marie-Tooth Disease CMT REFLEX,AARS, AIFM1, ARHGEF10, ATL1, ATP7A, BAG3, BICD2, BSCL2, CCT5, DCTN1, DHTKD1, DNAJB2, DNM2,DNMT1, DYNC1H1, EGR2, FAM134B, FBLN5, FGD4, FIG4, GAN, GARS, GDAP1, GJB1, GNB4, HARS, HEXA, HINT1, HK1, HOXD10,HSPB1, HSPB3, HSPB8, IGHMBP2, IKBKAP, INF2, KARS, KIF1A, KIF1B, KIF5A, LAS1L, LITAF, LMNA, LRSAM1, MARS, MED25, MFN2,MPZ, MTMR2, MYH14, NDRG1, NEFL, NGF, NTRK1, PDK3, PLEKHG5, PMP22, PRNP, PRPS1, PRX, RAB7A, REEP1, SBF1, SBF2, SCN9A,SETX, SH3TC2, SLC12A6, SLC5A7, SOX10, SPTLC1, SPTLC2, TDP1, TFG, TRIM2, TRPV4, WNK1, YARS 2012151 Charcot-Marie-Tooth (CMT) and Related Hereditary Neuropathies Panel Sequencing Charcot-Marie-Tooth Disease CMT SEQ, AARS, AIFM1, ARHGEF10, ATL1, ATP7A, BAG3, BICD2, BSCL2, CCT5, DCTN1, DHTKD1, DNAJB2, DNM2,DNMT1, DYNC1H1, EGR2, FAM134B, FBLN5, FGD4, FIG4, GAN, GARS, GDAP1, GJB1, GNB4, HARS, HEXA, HINT1, HK1, HOXD10,HSPB1, HSPB3, HSPB8, IGHMBP2, IKBKAP, INF2, KARS, KIF1A, KIF1B, KIF5A, LAS1L, LITAF, LMNA, LRSAM1, MARS, MED25, MFN2,MPZ, MTMR2, MYH14, NDRG1, NEFL, NGF, NTRK1, PDK3, PLEKHG5, PMP22, PRNP, PRPS1, PRX, RAB7A, REEP1, SBF1, SBF2, SCN9A,SETX, SH3TC2, SLC12A6, SLC5A7, SOX10, SPTLC1, SPTLC2, TDP1, TFG, TRIM2, TRPV4, WNK1, YARS 2012609 CHARGE Syndrome, CHD7 Sequencing CHARGE Syndrome 2012717 CHARGE Syndrome (CHD7) Sequencing, Fetal CHARGE Syndrome 2002065 Chimerism, Recipient Pre-Transplant Chimerism STR-PRE 2002067 Chimerism, Donor Chimerism STR-DONOR 2002064 Chimerism, Post-Transplant, Sorted Cells Chimerism STR-POSTSC 2002066 Chimerism, Post-Transplant Chimerism STR-POST 3000544 Chronic Granulomatous Disease Panel (CYBB Sequencing and NCF1 Exon 2 GT Deletion) Chronic Granulomatous Disease CGD PAN, Cytochrome b-Positive, Type I, NCF1 Deficiency, Niemann-Pick Disease Type A, p47-PHOX, Soluble Oxidase Component II 3000541 Chronic Granulomatous Disease, X-Linked (CYBB) Sequencing Chronic Granulomatous Disease CYBB FGS , Cytochrome b-Positive, Type I, NCF1 Deficiency, Niemann-Pick Disease Type A, p47-PHOX, Soluble Oxidase Component II 2006366 Chronic Granulomatous Disease (NCF1) Exon 2 GT Deletion Chronic Granulomatous Disease NCF1, Cytochrome b-Positive, Type I, NCF1 Deficiency, Niemann-Pick Disease Type A, p47-PHOX, Soluble Oxidase Component II 2006261 Citrin Deficiency (SLC25A13) Sequencing Citrin Deficiency CITRIN FGSCitrin DeficiencyCitrullinemia Type II Failure to Thrive and Dyslipidemia Caused by Citrin Deficiency Neonatal Intrahepatic Cholestasis Caused by Citrin Deficiency 2007069 Citrullinemia, Type I (ASS1) Sequencing Citrullinemia, Type I 2011157 Cobalamin/Propionate/Homocysteine Metabolism Related Disorders Panel, Sequencing (25 Genes) and Deletion/Duplication (24 Genes) Cobalamin/Propionate/Homocysteine Metabolism Related Disorders VB12 PANEL, "ABCD4, ACSF3, AMN, CBS, CD320, CUBN, GIF, HCFC1, LMBRD1, MAT1A, MCEE, MMAA, MMAB, MMACHC, MMADHC, MTHFR, MTR, MTRR, MUT, PCCA, PCCB, SUCLA2, SUCLG1, TCN1, TCN2Methylmalonic aciduria and homocystinuria, cblJ typeCombined malonic and methylmalonic aciduriaMegaloblastic anemia-1, Norwegian typeHomocystinuria due to cystathionine beta-synthase deficiencyMethylmalonic aciduria due to transcobalamin receptor defectMegaloblastic anemia-1, Finnish typeIntrinsic factor deficiencyMethylmalonic acidemia and homocysteinemia, cblX type Methylmalonic aciduria and homocystinuria, cblF typeMethionine adenosyltransferase deficiencyMethylmalonyl-CoA epimerase deficiencyMethylmalonic aciduria, cblA typeMethylmalonic aciduria, cblB typeMethylmalonic aciduria and homocystinuria, cblC typeMethylmalonic aciduria and homocystinuria, cblD typeHomocystinuria due to deficiency of N(5,10)-methylenetetrahydrofolate reductase activityHomocystinuria-megaloblastic anemia, cblG typeHomocystinuria-megaloblastic anemia, cbl E typeMethylmalonic aciduria due to methylmalonyl-CoA mutase deficiencyPropionic acidemiaMitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria)Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria)Transcobalamin I deficiencyTranscobalamin II deficiency 2013386 Congenital Adrenal Hyperplasia (CAH) (21-Hydroxylase Deficiency) Common Mutations Congenital Adrenal Hyperplasia (CAH) 2006220 Congenital Amegakaryocytic Thrombocytopenia (CAMT) Sequencing Congenital Amegakaryocytic Thrombocytopenia CAMT FGS, GeneDx 2008610 Creatine Transporter Deficiency (SLC6A8) Sequencing and Deletion/Duplication Creatine SLC6A8 FGA, SLC6A8-Related Creatine Transporter Deficiency, SLC6A8 Deficiency 2008615 Creatine Transporter Deficiency (SLC6A8) Sequencing Additional Technical Information Creatine SLC6A8 FGS, SLC6A8-Related Creatine Transporter Deficiency, SLC6A8 Deficiency 0051110 Cystic Fibrosis (CFTR) Sequencing Cystic Fibrosis CF-CFTR, Diagnostic, CF 0051640 Cystic Fibrosis (CFTR) Sequencing with Reflex to Deletion/Duplication Cystic Fibrosis CFTR FGA, Diagnostic, CF 2013661 Cystic Fibrosis (CFTR), 165 Pathogenic Variants Cystic Fibrosis CF VAR 2013662 Cystic Fibrosis (CFTR), 165 Pathogenic Variants, Fetal Cystic Fibrosis CF VAR FE 2013663 Cystic Fibrosis (CFTR), 165 Variants with Reflex to Sequencing Cystic Fibrosis CF VAR SEQ 2013664 Cystic Fibrosis (CFTR), 165 Variants with Reflex to Sequencing and Reflex to Deletion/Duplication Cystic Fibrosis CFVAR COMP 2014547 Cytochrome P450 2D6 (CYP2D6) 15 Variants and Gene Duplication Cytochrome P450 CYP 2D6, Tamoxifen, Pharmacogenetics (PGx), Schizophrenia, Breast Cancer, breast biomarkers 2012769 Cytochrome P450 2C19, CYP2C19 - 9 Variants Cytochrome P450 CYP2C19, Pharmacogenetics (PGx), Schizophrenia, Breast Cancer, breast biomarkers 2012766 Cytochrome P450 2C9, CYP2C9 - 2 Variants Additional Technical Information Cytochrome P450 CYP2C9, Warfarin Sensitivity, Pharmacogenetics (PGx) 2012740 Cytochrome P450 3A5 Genotyping, CYP3A5, 2 Variants Cytochrome P450 2013098 Cytochrome P450 Genotype Panel Cytochrome P450 CYP PAN 2006234 Diamond-Blackfan Anemia (RPL5) Sequencing Diamond-Blackfan Anemia RPL5 FGS, GeneDx 2006236 Diamond-Blackfan Anemia (RPL11) Sequencing Diamond-Blackfan Anemia RPL11 FGS 2006238 Diamond-Blackfan Anemia (RPS19) Sequencing Diamond-Blackfan Anemia RPS19 FGS 2011241 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication with Reflex to Sequencing Duchenne/Becker Muscular Dystrophy DMD REFLEX, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011235 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication Duchenne/Becker Muscular Dystrophy DMD DD, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011153 Duchenne/Becker Muscular Dystrophy (DMD) Sequencing Duchenne/Becker Muscular Dystrophy DMD SEQ, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011231 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication, Fetal Duchenne/Becker Muscular Dystrophy DMD DD FE, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2006244 Dyskeratosis Congenita, Autosomal (TERC) Sequencing Dyskeratosis Congenita TERC FGS, GeneDx 2006228 Dyskeratosis Congenita, X-linked (DKC1) Sequencing Dyskeratosis Congenita DKC1 FGS 2011241 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication with Reflex to Sequencing Dystrophinopathies DMD REFLEX, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011235 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication Dystrophinopathies DMD DD, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011153 Duchenne/Becker Muscular Dystrophy (DMD) Sequencing Dystrophinopathies DMD SEQ, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 2011231 Duchenne/Becker Muscular Dystrophy (DMD) Deletion/Duplication, Fetal Dystrophinopathies DMD DD FE, Dystrophin, Duchenne, Becker, Dystrophinopathy, Dystrophinopathies, DMD, BMD 0080351 Ehlers-Danlos Syndrome Type VI Screen, Urine Ehlers-Danlos Syndrome Type VI (Kyphoscoliotic Form) EDS6Ehlers-Danlos Syndrome, Kyphoscoliotic FormEDS Kyphoscoliotic FormEDS Type VIEDS VIEhlers-Danlos Syndrome Type VILysyl-Hydroxylase DeficiencyEhlers-Danlos Syndrome Type VIANevo SyndromePLOD1Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1EDSVIEDS6EDS 6 2005559 Ehlers-Danlos Syndrome Kyphoscoliotic Form, Type VI (PLOD1) Sequencing and Deletion/Duplication Ehlers-Danlos Syndrome Type VI (Kyphoscoliotic Form) EDS-VI FGA 2005360 Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing and Deletion/Duplication Endocrine Cancer MEN1 FGA, Multiple endocrine adenomatosis, Wermer syndrome, Multiple Endocrine Neoplasias (MEN) 2005359 Multiple Endocrine Neoplasia Type 1 (MEN1) Sequencing Endocrine Cancer MEN1 FGS, Multiple endocrine adenomatosis, Wermer syndrome, Multiple Endocrine Neoplasias (MEN) 0051390 Multiple Endocrine Neoplasia Type 2 (MEN2), RET Gene Mutations by Sequencing Endocrine Cancer MEN2 SEQ, Thyroid Cancer, Pheochromocytoma, Multiple Endocrine Neoplasias (MEN), MEN 2A, MEN 2B, familial medullary thyroid carcinoma, FMTC, RET proto-oncogene 2002965 Von Hippel-Lindau (VHL) Sequencing and Deletion/Duplication Endocrine Cancer VHL FGA, Brain Tumors, Pheochromocytoma 2002970 Von Hippel-Lindau (VHL) Sequencing Endocrine Cancer VHL FGS, Congenital polycythemia 2007167 Hereditary Paraganglioma-Pheochromocytoma (SDHB, SDHC, and SDHD) Sequencing and Deletion/Duplication Panel Endocrine Cancer 2012032 Cancer Panel, Hereditary, Sequencing and Deletion/Duplication, 47 Genes Endocrine Cancer CANCERPAN, Lynch syndrome, breast cancer, multiple endocrine neoplasia, melanoma, retinoblastoma, paraganglioma, Li-Fraumeni, familial adenomatous polyposis, Peutz-Jegher, HNPCC, inherited cancer, renal cancer, GI cancer, colorectal cancer, NGS cancer panel 2006948 SDHB with Interpretation by Immunohistochemistry Endocrine Cancer 2011461 Hereditary Paraganglioma-Pheochromocytoma (SDHA) Sequencing Additional Technical Information Endocrine Cancer SDHA FGS 2007108 Hereditary Paraganglioma-Pheochromocytoma (SDHB) Sequencing and Deletion/Duplication Additional Technical Information Endocrine Cancer 2007117 Hereditary Paraganglioma-Pheochromocytoma (SDHC) Sequencing and Deletion/Duplication Additional Technical Information Endocrine Cancer 2002722 PTEN-Related Disorders Sequencing Endocrine Cancer PTEN FGS, PTEN hamartoma tumor, PHTS, Cowden, CS, Bannayan-Riley-Ruvalcaba, BRRS, Proteus, PS, Proteus-like, PSL, macrocephaly, autism 2007122 Hereditary Paraganglioma-Pheochromocytoma (SDHD) Sequencing and Deletion/Duplication Additional Technical Information Endocrine Cancer 2002470 PTEN-Related Disorders Sequencing and Deletion/Duplication Endocrine Cancer PTEN FGA, PTEN hamartoma tumor, PHTS, Cowden, CS, Bannayan-Riley-Ruvalcaba, BRRS, Proteus, PS, Proteus-like, PSL, macrocephaly, autism 2009313 Li-Fraumeni (TP53) Sequencing and Deletion/Duplication Endocrine Cancer TP53 FGA, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2009302 Li-Fraumeni (TP53) Sequencing Endocrine Cancer TP53 FGS, p53, TP53, Li Fraumeni, adrenocortical, sarcoma, chompret 2007533 Progressive Myoclonic Epilepsy (PME) Panel, Sequence Analysis and Exon-Level Deletion/Duplication Additional Technical Information Epilepsy PROG EPIL, seizures, PME, myoclonus, Lafora, Unverricht-Lundborg, neuronal ceroid lipofuscinoses, NCL, PRICKLE1, EPM2A, EPM2B, NHLRC1, CSTB, PPT1, CLN1, CLN2, CLN3, CLN5, CLN6, CLN7, CLN8, CLN10, TPP1, MFSD8, CTSD, GeneDx 2006069 Febrile Seizures Panel Epilepsy FEBRIL PAN 2007545 Childhood-Onset Epilepsy Panel, Sequencing and Deletion/Duplication Additional Technical Information Epilepsy CHILD EPIL, Early-onset epileptic encephalopathy, SCN1A, Sodium channel protein type 1 alpha, PCDH19, Protocadherin-19, SLC2A1, Solute carrier family 2, facilitated glucose transporter member 1, POLG, DNA polymerase subunit gamma-1, SCN2A, Sodium channel protein type 2 alpha, Generalized epilepsy with febrile seizures plus, GEFS+, SCN1A, Sodium channel protein type 1 alpha, SCN1B, Sodium channel subunit beta-1, GABRG2, Gamma-aminobutyric acid receptor subunit gamma-2, SCN2A, Sodium channel protein type 2 alpha, Juvenile Myoclonic Epilepsy, JME, EFHC1, EF-hand domain-containing protein 1, CACNB4, Voltage-dependent L-type calcium channel subunit beta-4, GABRA1, Gamma-aminobutyric acid receptor subunit alpha-1, Progressive Myoclonic Epilepsy, EPM2A, Laforin, NHLRC1, EPM2B, NHL repeat-containing protein 1, malin, CSTB, Cystatin-B, PRICKLE1, Prickle-like protein 1, Autosomal Dominant Focal Epilepsies, CHRNA4, Neuronal acetylcholine receptor alpha-4, CHRNB2, Neuronal acetylcholine receptor beta-2, CHRNA2, Neuronal acetylcholine receptor alpha-2, LGI1, Leucine-rich glioma-inactivated protein 1, atypical Rett syndromes, MECP2, Methyl CpG binding protein 2, CDKL5, Cyclin-dependent kinase-like 5, FOXG1, Forkhead box protein G1, Angelman, Angelman-like, Pitt-Hopkins, UBE3A, Ubiquitin protein ligase E3A, SLC9A6, Sodium/hydrogen exchanger 6, TCF4, Transcription factor 4, NRXN1, Neurexin-1, CNTNAP2, Contactin-associated protein-like 2, Mowat-Wilson, ZEB2, Zinc finger E-box-binding, homeobox 2, Creatine deficiency, GAMT, Guanidinoacetate N-methyltransferase, GATM, Glycine amidinotransferase, mitochondrial, Neuronal Ceroid Lipofuscinoses, NCL, PPT1, CLN1, Palmitoyl-protein thioesterase 1, TPP1, CLN2,Tripeptidyl-peptidase 1, CLN3, Battenin, CLN5, Ceroid-lipofuscinosis neuronal protein 5, CLN6, Ceroid-lipofuscinosis neuronal protein 6, MFSD8, CLN7, Major facilitator superfamily domain-containing protein 8, CLN8, Ceroid-lipofuscinosis neuronal protein 8, CTSD, CLN10, Cathepsin D, Adenosuccinate lyase deficiency, ADSL, Adenylosuccinate lyase, SYN1, Synapsin-1, Microcephaly with early-onset intractable seizures and developmental delay, MCSZ, PNK, Bifunctional polynucleotide, phosphatase/kinase, seizures, GeneDx 2007535 Infantile-Onset Epilepsy Panel, Sequencing and Deletion/Duplication Additional Technical Information Epilepsy INFANT EPIL; SCN1A; PCDH19; SLC2A1; POLG; SCN2A; SCN1A; SCN1B; GABRG2; EFHC1; CACNB4; GABRA1; EPM2A; NHLRC1; EPM2B; CSTB; PRICKLE1; CHRNA4; CHRNB2; CHRNA2; LGI1; MECP2; CDKL5; FOXG1; UBE3A; SLC9A6; TCF4; NRXN1; CNTNAP2; ZEB2; GAMT; GATM; PPT1; CLN1; TPP1; CLN2; CLN3; CLN5; CLN6; MFSD8; CLN7; CLN8; CTSD; CLN10; ADSL; SYN1; PNKP; benign familial neonatal seizures; generalized epilepsy with febrile seizures; juvenile myoclonic epilepsy; progressive myoclonic epilepsy; autosomal dominant focal epilepsies; Rett/atypical Rett syndromes; Angelman/Angelman-like/Pitt-Hopkins syndromes; Mowat-Wilson syndrome; creatine deficiency syndromes; neuronal ceroid lipofuscinoses; adenosuccinate lyase deficiency; epilepsy with variable learning and behavioral disorders; microcephaly with early onset intractable seizures and developmental delay", GeneDx 2006332 Exome Sequencing with Symptom-Guided Analysis Exome EXOME SEQ 2006336 Exome Sequencing Symptom-Guided Analysis, Patient Only Exome EXOSEQ PRO 0030192 APC Resistance Profile with Reflex to Factor V Leiden Factor V Leiden APC R, Venous thrombosis, Thromboembolism, Thrombophilia, clotting 0097720 Factor V Leiden (F5) R506Q Mutation Factor V Leiden FACV, Venous thrombosis, Thromboembolism, Thrombophilia, clotting 2001549 Factor V, R2 Mutation Factor V Leiden F5 R2, Venous thrombosis, Thromboembolism, Thrombophilia, clotting, A4070G 2003220 Factor XIII (F13A1) V34L Variant (assess thrombotic risk in Caucasians) Factor XIII (F13A1) V34L Variant FAC 13 MUT, Venous thrombosis, Thromboembolism, Thrombophilia, clotting 2004915 Familial Adenomatous Polyposis Panel: APC Sequencing, APC Deletion/Duplication, and MYH 2 Mutations Familial Adenomatous Polyposis FAP Panel, Familial Adenomatious Polyposis familial cancer, Colorectal Cancer, colon cancer, CRC, polyps, FAP, familial cancer 2004863 Familial Adenomatous Polyposis (APC) Sequencing Familial Adenomatous Polyposis APC FGS, Colorectal Cancer, colon cancer, CRC, polyps, Familial Adenomatious Polyposis FAP, familial cancer 2004911 MUTYH-Associated Polyposis (MUTYH) 2 Mutations Familial Adenomatous Polyposis MYH SEQ, Hereditary Colorectal Cancer, MAP, MUTH Associated Polyposis 2006191 MUTYH-Associated Polyposis (MUTYH) Sequencing Familial Adenomatous Polyposis MUTYH, FGS, MYH 2006307 MUTYH-Associated Polyposis (MUTYH) 2 Mutations with Reflex to Sequencing Familial Adenomatous Polyposis MUTYH RFLX MYH 0051463 Dysautonomia, Familial (IKBKAP), 2 Variants Familial Dysautonomia IKBKAP, Jewish Genetic Disease 2002658 Familial Mediterranean Fever (MEFV) Sequencing Familial Mediterranean Fever (MEFV) FMF FGS, DNA 2001961 Familial Mutation, Targeted Sequencing

The following genes are available:ACADVL, ACADM, ACVRL1, APC, ASS1, ATP7A, BMPR1A, BMPR2, BTD, CCM1, CCM2, CCM3, CDKL5, CFTR, COL4A5, CYP1B1, ENG, F8, F9, FBN1, G6PD, GALT, GJB2; HBA1, HBA2, HBB, INSR, LMNA, MECP2,MEFV, MEN1, MLH1, MSH2; MSH6, MUTYH, MYH3, NF1, OTC, PLOD1, PMS2; PRSS1, PTEN, PTPN11, RASA1, RET, SDHB, SDHC, SDHD, SLC22A5, SLC25A13, SMAD4, SPRED1, SPINK1, SOS1, STK11, TACI, TGFBR1, TGFBR2, UBE3A, VHL, VWF

Read more:
Molecular Genetics | ARUP Laboratories

Posted in Molecular Genetics | Comments Off on Molecular Genetics | ARUP Laboratories

Anti-Aging, Regeneration and Stem Cell Supplements

Posted: August 7, 2018 at 7:42 pm

Dr Bryant Villeponteau the formulator of Stem Cell 100 and other Life Code nutraceuticals was recently interviewed by Dr Mercola who owns the largest health web site on the internet. Dr. Villeponteau is also the author of Decoding Longevity an new book which will be released during December. He is a leading researcher in novel anti-aging therapies involving stem cells an area in which he has been a pioneer for over three decades.

Stem cell technology could have a dramatic influence on our ability to live longer and replace some of our failing parts, which is the inevitable result of the aging process. With an interest in aging and longevity, Dr. Villeponteau started out by studying developmental biology. ?If we could understand development, we could understand aging,? he says. Later, his interest turned more toward the gene regulation aspects. While working as a professor at the University of Michigan at the Institute of Gerontology, he received, and accepted, a job offer from Geron Corporation?a Bay Area startup, in the early ?90s.

?They were working on telomerase, which I was pretty excited about at the time. I joined them when they first started,? he says. ?We had an all-out engagement there to clone human telomerase. It had been cloned in other animals but not in humans or mammals.?

If you were to unravel the tip of the chromosome, a telomere is about 15,000 bases long at the moment of conception in the womb. Immediately after conception, your cells begin to divide, and your telomeres begin to shorten each time the cell divides. Once your telomeres have been reduced to about 5,000 bases, you essentially die of old age.

?What you have to know about telomerase is that it?s only on in embryonic cells. In adult cells, it?s totally, for the most part, turned off, with the exception of adult stem cells,? Dr. Villeponteau explains. ?Adult stem cells have some telomerase ? not full and not like the embryonic stem cells, but they do have some telomerase activity.?

Most of the research currently being done, both in academia and industrial labs, revolves around either embryonic stem cells, or a second type called induced pluripotent stem cells (iPS). Dr. Villeponteau, on the other hand, believes adult stem cells are the easiest and most efficient way to achieve results.

That said, adult stem cells do have their drawbacks. While they?re your own cells, which eliminates the problem of immune-related issues, there?s just not enough of them. Especially as you get older, there are fewer and fewer adult stem cells, and they tend to become increasingly dysfunctional too. Yet another hurdle is that they don?t form the tissues that they need to form

To solve such issues, Dr. Villeponteau has created a company with the technology and expertise to amplify your adult stem cells a million-fold or more, while still maintaining their ability to differentiate all the different cell types, and without causing the cells to age. Again, it is the adult stem cell?s ability to potentially cure, or at least ameliorate, many of our age-related diseases by regenerating tissue that makes this field so exciting.

Dr Villeponteau believes you can add many years, likely decades, to your life simply by eating right, exercising (which promotes the production of muscle stem cells, by the way) and living an otherwise clean and healthy lifestyle. Extreme life extension, on the other hand, is a different matter.

His book, Decoding Longevity, covers preventive strategies to prolong your life, mainly diet, exercise, and supplements. A portion of the book also covers future developments in the area of more radical life extension, such as stem cell technology.

If you would like to read the entire interview here is a link to the text version:

Transcript of Interview With Dr. Bryant Villeponteau by Dr. Joseph Mercola

Read the original here:
Anti-Aging, Regeneration and Stem Cell Supplements

Posted in Michigan Stem Cells | Comments Off on Anti-Aging, Regeneration and Stem Cell Supplements

Montana Stem Cell Therapy – Cordblood Search Tools

Posted: August 5, 2018 at 6:54 am

Present and Future of Stem Cell Therapy in Montana

Cord blood banking near Montana is a significant and comparatively little-known means of getting stem cells to treat a broad range of ailments. This post looks at the possible gains and what it's, how it works. It's targeted at future parents who would like to find out more. Here is a post that is insightful into the current state of play and its possibility for the future.

Stem cell banking freezes the blood from the umbilical cords of your infant for possible future use against disorders grown by your family. This blood source can already successfully treats many serious medical conditions. It's really worth assessing the possible advantages if you live in the Montana area.

bone marrow remains the most common source for gathering stem cells in Montana to date. The downside to bone marrow transplants s that they can extremely invasive and complex and may even result in constant uncomfortableness for the donors. Embryos are also a solution for stem cells but tend to be a massively controversial issue in Montana , which leaves umbilical cord blood stem cell therapy. Its the safest and least invasive form of stem cell therapy.

Extensive studies near Montana have showed that stem cell therapy from umbilical cord blood stem cells has countless advantages over the genes of circulatory blood and marrow derived genes and bone marrow. Although currently bone marrow is ahead of umbilical cord blood for certain specific diseases and procedures, it is often agreed that favor is slowly weighing in more on the side of cord blood.

An example of blood stem cell therapy in the Montana area would be the use of stem cells for conditions such as leukemia, lymphomas, immune deficiencies, sickle cell anemia and certain cancers, all of which have proven to be deadly. On the other hand, the use of ones own stem cells to help with certain ailments may not be advisable. When ones own stem cells are used to treat something such as leukemia, it wont be effective because the stem cells will completely take over and replace the afflicted cells that caused the disease in the first place. However, if the patient has a sibling that donated stem cells then they may be a good enough match to hopefully offset the disease. It seems almost certain that the stem cell therapy industry will continue to grow in Montana.

The future looks bright for stem cell therapy by cord blood cells in Montana, despite the minority status of transfusions in the world. It is strongly believed by scientists that ones own individual cord blood will or could at some point be beneficial in the successful treatments of cancer. The reason behind this is because most adult-style cancers arent solely derived from genetics, whereas pediatric cancers are.

Researchers around Montana are also discovering ways to manipulate the gene that is leukemia so that in the future it may be a possibility that your own blood could cure your cancer, thus making umbilical cord blood banking for future stem cell therapy even more valuable than it already is. There are even animal stem cell therapy experiments that are pushing the boundaries of conventional stem cell therapy and could ultimately mean that stem cells could cure spinal problems, strokes, heart failure and even diabetes.

The possibilities of stem cell therapy in Montana are truly limitless just as all gene-related cures. Its even possible that neurological diseases and motor function disorders could tackled and cured with cord blood stem cell therapy. Other targeted possibilities on the list of stem cell therapy include Alzheimers and Parkinsons disease.

At this point in time public cord blood banks receive a small amount of umbilical cord blood for use in stem cell therapy and research. The reason for this is that many people are opting to store their umbilical cord blood privately which essentially insures their family against debilitating, deadly illnesses. Even though the amount of people storing cord blood for stem cell therapy, the more diseases that become treatable with stem cells, the amount of people that harvest theirs in Montana will skyrocket.

Whether you decide to store umbilical cord blood publically or privately there is usually a limited amount of stem cells in a unit of stored umbilical cord blood, which means that the amount of cord blood available is only really effective for treating someone up to a certain age. Processes to increase the amount of stem cells in a single unit of cord blood are being tested with clinical trials near Montana.

Excerpt from:
Montana Stem Cell Therapy - Cordblood Search Tools

Posted in Montana Stem Cells | Comments Off on Montana Stem Cell Therapy – Cordblood Search Tools

Nuclear Medicine – Molecular Imaging – Nuclear Medicine …

Posted: August 3, 2018 at 3:49 am

TRUE DISCOVERY AWAITS

It takes a certain mind to go in search of true discovery. In nuclear medicine, they are the clinical researchers looking to set new standards of care, the practitioners working to deliver better outcomes for the patients they see every day and the cardiologists seeking a better understanding of the heart. While they all have the same goal, their needs are different and cant all be met with one system or technology.

Nuclear medicine is an excellent choice for physicians at the forefront of medicine. It has a wide range of available radioisotopes with various energy emission levels and longer half-lives. It also has the flexibility to explore multiple pathways in a single session. These are some of the reasons why we made a commitment to realizing the full potential of and growing this modality.

This commitment involves making nuclear medicine technology more accessible and enabling it to provide results that are more valuable to referring physicians. It means driving down daily operational costs and innovating in four key areas: image quality, dose reduction, exam speeds and quantitative applications. All with the end result of enabling better clinical and economic outcomes.

It also includes our vision for a fully digital nuclear medicine experience. An experience that starts with best-in-class hardware and software that collects your data in the cloud and then converts that data into actionable insights through deep learning and analytics. All of our systems are designed to leverage this fully digital vision right away. If you are interested in digital detection technology as well, you can choose between a system already fitted with CZT-based digital detectors or an adaptable, digital-detection-ready system.

No matter what nuclear medicine technology you choose, you will have the tools you need to go in search of true discovery.

Accurate quantitation

High image quality

Short exams

Dose efficiency

Expanded access

Fully digital experience

Excerpt from:
Nuclear Medicine - Molecular Imaging - Nuclear Medicine ...

Posted in Molecular Medicine | Comments Off on Nuclear Medicine – Molecular Imaging – Nuclear Medicine …

Amniotic Stem Cell Injections, Advanced Muscle Integration …

Posted: August 3, 2018 at 3:44 am

Three weeks ago, I traveled to Salt Lake City for a three-day health hacking journey that involved advanced muscle integration technique, high dose vitamin C therapy, stem cell injections and more. I received so many questions about the journey that I figured Id give you the complete lowdown in todays article, complete with videos and other helpful downloads.

Enjoy the knowledge youll discover below, and leave any questions or comments under the article.

On my first day in Salt Lake City, I visited the offices of Dr. Craig Buhler for a four-hour Advanced Muscle Integration Technique (AMIT) session. I firstheard of Craig,also know as Dr. Two Fingers in Tim Ferrisss book 4-Hour Body, when I interviewed him several years ago about how he can make injuries and issues that have nagged the body for as long as decades, completely disappear with special techniques and also how his technique can keep acute injuries from becoming long-term problems.

AMIT practitioners can predict injuries by examining and identifying instabilities in the body, which in most cases lead to injury. The therapies utilized in AMIT procedures allow for rapid corrections of instabilities, resulting in improved function, removal of pain and an overall new level of performance.

There are many things that can aid in shutting a muscle down. Simply being active and doing the many day-to-day activities put stresses on your body and can create imbalances. Strenuous activity, athletics, daily recreation, and nutritional habits are all examples of things that can contribute to muscles becoming inhibited. Craig seespatients with as little as 10-15 muscles shut down and some with 70-80 muscles that are shut down.

In activating a muscle an AMIT practitioner must stimulate 7 reflux points using his hands. There is one neurovascular point, one neurolymphatic point, two organ reflex points, an acupressure point, and the origin an insertion of the muscle itself. After stimulating these points together, the doctor will retest the muscle to determine that the muscle has become strong. Heres an example of Craig turning my glutes back on and the subsequent range of motion increase:

In addition, Craig performed a nasal chiropractic balloon adjustment on my sinuses. This blew my mind. Watch the video below to see what I mean:

Additional resources from the Dr. Buhler clinic visit:

My podcast with Dr. Craig Buhler

Dr. Buhlers website

On Day 2, I drove nearly two hours from Salt Lake to Pocatello, Idaho to visit Dr. Jason Wests clinic (along with Naomi Whittel, who I interviewed during the drive for the episode Drinking Sperm, Smearing Mayonnaise On Your Face, Protein Cycling & A Cell Death Deep Dive With Author Naomi Whittel)

What youre about to witness is one of the most cutting-edge protocols in naturopathic and chiropractic care. Dr. Jason West who operates the world-famous West Clinic in Pocatello, ID not only administered high-dose Vitamin C and an athlete cocktail into my body but also performed the procedure in this video.

Other treatments done at Jasons clinic included:

-IV vitamin C therapy -Stomach neural therapy -Nerve of maigne therapy -Regenerative injection therapy with prolozone (proliferative therapy using ozone)

Upon leaving his clinic, my body felt like a new man with several of the gastrointestinal and low back complaints I had completely gone.

Additional resources from the Dr. Jason West clinic visit:

-Naomi Whittels book,Glow15: A Science-Based Plan to Lose Weight, Revitalize Your Skin, and Invigorate Your Life

My podcast with Naomi Whittel

Dr. Jason Wests clinic

-PDF Download: Neural Therapy handout

-PDF Download: Prolozone Therapy handout

On Day 3, I traveled back to Salt Lake City for an amniotic stem cell injection at the East West Clinicowned by Dr. Regan Archibald. Watch the video below to see the entire stem cell IV and injection procedure performed on me:

Regan explained the procedure as follows:

On March 20th, my team used 1 ml of a product called StemShot from Utah Cord Bank in your back. The areas targeted were T12/L1 and L2. 1-1 1/2 deep injections were administered into tender areas along the erector muscles of the spine, primarily the longissimus dorsum and spinalis. Reversal of hypertonicity in the paraspinals, reducing inflammation in the spinal nerves, and repair of soft tissue damage was the intent of this procedure. The fact that you palpated exactly where the troubled areas existed in your paraspinals and the ease of point location with your anatomy allowed for a successful injection. We typically will use ultrasound guidance in more difficult cases but we dont use C-arm as the gamma rays have the potential to damage healthy stem cells. Stem cells have the ability to home into damaged areas and weve had a high level of success with our spinal treatments.

You also received a 1 ml IV infusion of StemVive from Utah Cord Bank. The StemVive product still has the same cell count, growth factor, and cytokine make-up as the StemShot, the only difference is that in this product some of the extracellular matrix has been sacrificed so that the cells can make it through the lungs intact. 90-95% of the cells will stop in the lungs initially but within 24 hours they can be found in every tissue compartment in your body. This is also the same product used in our brain treatments intranasally.

You also received acupuncture following your procedures. Points were selected and needled with 38 gauge acupuncture needles on your Bladder, Liver, Governing Vessel, and Kidney meridians to increase blood circulation in your spine and to promote intra stem cell release. Several papers have suggested that acupuncture improves the response rate of stem cell therapy.

Here are several studies that delve into the fascinating links explaining the relationship between acupuncture and stem cell injections:

Electro-acupuncture promotes differentiation of mesenchymal stem cells, regeneration of nerve fibers and partial functional recovery after spinal cord injury

The Mechanism of Acupuncture Beyond Neurohumoral Theory

Adult Neurogenesis and Acupuncture Stimulation at ST36

Additional resources and videos from my stem cell injection at East West Clinic:

-YouTube:Brain Regeneration with Intranasal Cell Therapy

-YouTube:Stem Cell Pain and Health Transformation

-PDF: Post Stem Cell Follow Up

East West Clinic, mention Ben for a free consultation

Occasional getaways like this to reboot your body are something I highly encourage for anyone who can take the time and spend the resources to do it. Consider these type of adventures to be an investment in your body that pays off for years to come (and stay tuned for details on a two-week full body reboot that I am organizing for 2019 in Switzerland!)

Do you have questions, comments or feedback for Dr. Buhler, Dr. West, Dr. Archibald, Naomi or me? Leave your thoughts below and one of us will reply!

Ask Ben a Podcast Question

View original post here:
Amniotic Stem Cell Injections, Advanced Muscle Integration ...

Posted in Idaho Stem Cells | Comments Off on Amniotic Stem Cell Injections, Advanced Muscle Integration …

Page 1,428«..1020..1,4271,4281,4291,430..1,4401,450..»